taxes on digital currency, Featured

[Shanghai 10 billion M&A Fund! 】The "Action Plan" proposes to strive to land a number of representative M&A cases in key industries by 2027, and cultivate about 10 internationally competitive listed companies in key industries such as integrated circuits, biomedicine and new materials.Since then, after continuing to Shenzhen and Anhui, Shanghai has also made efforts in mergers and acquisitions.

"The government's participation in M&A fund investment does not mean that the government will dominate the M&A business, but encourage market-oriented institutions and chain owners to lead the M&A business through the above-mentioned M&A fund or parent fund support." Bu Rixin believes.The policy is favorable for surprise attack and seize the opportunity to get on the bus > >For the biomedical industry, Bu Rixin told the reporter of science and technology innovation board Daily that the investment cycle of biomedicine is generally long, and it needs to go through multiple stages from research and development to listing.

"At present, the Yangtze River Delta has many excellent semiconductor enterprises and research institutions, while Shanghai has many top semiconductor design enterprises at home and abroad, such as Quanlun Electronics, Lanqi Technology, Fudan Microelectronics, Weir, Aojie Technology and Ziguang Zhanrui. The establishment of industrial mergers and acquisitions will help to integrate industry resources, promote industry agglomeration, and form a group of design companies with strength and key core technologies. " Yuan Shuai said.The "10 billion yuan M&A fund for integrated circuit design industry" stated in the Action Plan is considered by the market as a supplement to the 100 billion yuan parent fund for the three leading industries.In its view, this 10 billion M&A fund is not only 10 billion yuan, but also a way for the government to encourage and guide M&A through the amplification of M&A funds. "In short, whether it is the M&A fund of the integrated circuit design industry or the M&A fund of biomedicine, the core purpose is to guide the orderly development of the industry and avoid the dependence on the IPO path, leading to excessive competition in the industry."